PIM1 is an oncogenic serine/threonine kinase that promotes and maintains prostate tumorigenesis. To more fully understand the mechanism by which PIM1 promotes oncogenesis, we performed a chemical genetic screen to identify direct PIM1 substrates in prostate cancer cells. The PIM1 substrates we identified were involved in a variety of oncogenic processes, and included N-Myc Downstream-Regulated Gene 1 (NDRG1), which has reported roles in the suppression of cancer cell invasion and metastasis. NDRG1 is phosphorylated by PIM1 at serine 330 (pS330), and the level of NDRG1 pS330 is associated with high grade compared to low grade prostate tumors. While NDRG1 pS330 is largely cytoplasmic, total NDRG1 is both cytoplasmic and nuclear. Mechanistically, PIM1 phosphorylation of NDRG1 decreases its stability, reducing its interaction with AR, and thereby lowering expression of AR target genes.
INTRODUCTION
Pro-viral integration site for Moloney murine leukemia virus-1 (PIM1) is a protooncogene encoding a serine/threonine kinase 1, 2 . PIM1 is constitutively active and does not depend upon post-translational modifications for activation 3, 4 . As such, PIM1 is regulated primarily by transcription, including induction by cytokines through the JAK/STAT pathway 5 and by hypoxia 6 . PIM1 protein levels are also regulated translationally via its 5' UTR 7 and by the microRNA miR-33a 8 . PIM1 has been implicated as an oncogene in both hematological malignancies, such as large B cell lymphoma 9 , and cancers of epithelial origins, such as breast and prostate cancer [10] [11] [12] [13] .
Whereas absent or weak expression of PIM1 by immunohistochemistry are observed in most benign prostate samples, moderate to strong levels of PIM1 are evident in ~ 50% of prostate cancers 12 .
In mouse models of prostate cancer, conditional overexpression of PIM1 in prostate epithelial cells results in prostate intraepithelial neoplasia 13 . PIM1 also cooperates with c-MYC, an established oncogene, to promote advanced prostate adenocarcinoma 10 . We and others have previously shown that PIM1 phosphorylates the androgen receptor (AR) 14 , the main driver of prostate cancer and the main target in prostate cancer therapy 15, 16 . PIM1-mediated AR serine 213 phosphorylation (pS213) differentially impacts AR target gene expression and is correlated with prostate cancer recurrence 14, 17 . Given that deregulation of kinases is a hallmark of cancer 18 , we hypothesized that identifying PIM1 substrates and their phosphorylation sites in prostate cancer cells could help to elucidate PIM1's role in the disease, and help to identify cancers with active PIM1.
To identify PIM1 substrates and their phosphorylation sites in LNCaP cells, we coupled a chemical genetic screen with a peptide capture, mass spectrometry (MS)-based approach 19 . We mutated the PIM1 gatekeeper residue in the ATP binding site to accept a bulky ATP analog. By using an ATP analog labeled with a thiol group on the γ -phosphate, we were able specifically label PIM1 substrates even in the presence of other cellular kinases 20 .
A similar approach has revealed the direct substrates of AMPK, with unexpected roles in mitosis and cytokinesis 21, 22 ; CDK9, with functions in transcriptional termination through phosphorylation of the 5'-3' exonuclease XRN2 23 ; and CDK2, with a role in the DNA damage response by phosphorylation of NBS1, a necessary protein for DNA damage repair 24 . Overall, this is a rigorous approach that has revealed new substrates of kinases to yield novel mechanistic insights.
Several putative PIM1 substrates, including c-MYC, AR, and BAD, have been identified and found to be dysregulated in prostate cancer 14, 17, 25, 26 . Still, the mechanism by which PIM1 promotes prostate cancer is not fully understood. Our study identifies new PIM1 substrates in prostate cancer cells in a direct, unbiased manner. This revealed that PIM1 substrates are involved in a variety of cellular processes, ranging from cell cycle checkpoints, to nucleic acid metabolism, to transcriptional regulation, to cellular motility and invasion. By further exploring the PIM1-dependent phosphorylation of NDRG1, we find that PIM1-dependent phosphorylation reduces the function of NDRG1 as a metastasis suppressor.
RESULTS

Identification of PIM1 substrates in prostate cancer cells
We conducted a chemical genetic screen to identify direct PIM1 substrates and their phosphorylation sites in LNCaP cells. We used an analog-sensitive (AS) kinase-substrate detection method 27, 28 . To create the AS PIM1 kinase, we aligned the PIM1 amino acid sequence of the 33kDA PIM1 isoform 29 with other kinases for which AS mutants have been generated, and identified leucine 120 (L120) as the conserved gatekeeper residue (Suppl. Table 1 ). We mutated L120 to a smaller glycine residue (L120G) and generated pools of LNCaP cells stably expressing similar levels of either wild type PIM1 (LNCaP-WT PIM1) or AS PIM1 (LNCaP-AS PIM1). We tested the ability of AS PIM1 to utilize a series of bulky N 6 -substituted ATP analogs in cells by treating with digitonin, a mild permeabilizing agent. We then lysed the cells and added para-nitrobenzyl mesylate (pNBM) to alkylate thiophosphorylated proteins, and used a thiophosphate ester-specific antibody to reveal substrates by Western blot (Fig. 1A) . LNCaP cells harboring the AS PIM1 were able to utilize PhET-ATPγS, and to a lesser extent, Phe-ATPγS, to phosphorylate substrates. Cells expressing WT PIM1 were much less efficient at utilizing these analogs, whereas ATPγS is not specific for AS PIM1 (Fig. 1B) . Therefore, all subsequent thiophosphorylation experiments were performed with PheET-ATPγS as the ATP analog.
We have previously reported that AR is a substrate of PIM1 14 . To ensure that AS PIM1 retained its substrate specificity and could phosphorylate a known substrate, we immunoprecipitated ectopically expressed AR from 293T cells expressing either WT PIM1 or AS PIM1 and performed the thiophosphorylation assay. We also examined whether endogenous AR could be selectively thiophosphorylated in LNCaP-AS PIM1 as compared to LNCaP-WT PIM1 cells. Indeed, we found that AS PIM1 was able to use PhET-ATPγS to thiophosphorylate both ectopically expressed AR and endogenous AR in 293T and LNCaP cells, respectively.
However, WT PIM1 was much less effective (Figs. 1C-D). This indicates that the AS PIM1
retains specificity for a known substrate.
To identify PIM1 substrates and their phosphorylation sites, we treated LNCaP-WT PIM1
and LNCaP-AS PIM1 expressing cells with PhET-ATPγS ( Fig. 2A ), and isolated thiophosphorylated tryptic-peptides using iodoacetyl beads 27 . This was followed by selective release of the thiophosphorylated peptides with spontaneous hydrolysis using potassium peroxomonosulfate (OXONE), forming phosphopeptides. Liquid chromatography tandem mass spectrometry (LC-MS/MS) was used to identify protein substrates and their sites of phosphorylation.
To identify and prioritize high-confidence PIM1 substrates and phosphorylation sites, we used a stringent set of criteria to analyze the mass spectrometry data. Phosphopeptides found in the AS PIM1 datasets, but not in the WT PIM1 control datasets were selected. From a total of 25 protein substrates identified in two biological replicates of AS PIM1 samples (Suppl. Table 2) , 15 previously unidentified PIM1 substrates were represented in both replicates ( Fig. 2B -C). A PIM1 consensus motif logo was generated from the substrates found in this study (Fig. 2D ).
This motif conformed to the literature consensus PIM1 phosphorylation motif, R/K-X-R/K-H-X-S/T, where X is a small, neutral amino acid; and an acidic or basic residue (lysine or arginine) at the -3 and -5 positions from the phosphorylation site 30 . Therefore, these proteins likely represent high-confidence PIM1 substrates ( Fig. 2C , Suppl. Table 3 ). We first focused on candidates which strongly adhered to the PIM1 consensus motif, had high peptide counts, and had been previously linked to human prostate cancer. While no previously identified substrates such as AR or c-Myc were found in our screen, we believe our screen identifies the most robust substrates of PIM1 in LNCaP cells. However, we not think that the screen is exhaustive. For example, we previously showed that AR serine 213 is a target of PIM1. We were able to confirm this in LNCaP cells by immunoprecipitating AR from LNCaP expressing AS-PIM1 and show that it can be thiophosphorylated ( Fig 1D) . Given this result and that the identified substrates conform to the PIM1 consensus phosphorylation motif, we think that the paucity of known PIM1
substrates is not an issue of altered substrate specificity of the AS-PIM1, but rather low abundance of the previously recognized PIM1 substrates, low levels of phosphorylation, or an inability to capture the peptides on MS 21, 22 . The combination of our directed thiophosphorylation of AR from LNCaP cells expressing AS-PIM1, coupled with the phosphorylation motif analysis indicating extensive alignment to the PIM1 phosphorylation consensus sequence, gives us high confidence that the substrates we identified represent bone fide PIM1 substrates, even if the screen is not saturating.
Several of the PIM1 substrates we identified are involved in the regulation of RNA and DNA metabolism. For example, PUM1, a PUF family RNA-binding protein, regulates translation of sequence-specific genes by binding their 3' UTRs 31, 32 . Substrates NCOR1 and RNA polymerase II elongation factor (ELL) have been implicated in RNA polymerase II pausing and activation, respectively 33, 34 . Additional substrates identified in the screen, including CHMP7, TCOF1, NPAT, CLASP1, and KIF18A, have strong associations with mitosis, spindle formation, and microtubule depolymerization [35] [36] [37] [38] [39] [40] . These connections to mitosis are intriguing, since PIM1
is known to interact with nuclear mitotic apparatus protein (NuMa) and to promote cell cycle progression during mitosis 41 . Lastly, NDRG1, an established metastasis suppressor involved in cell motility, and has been shown to interact with the WNT receptor LRP6 to block WNT signaling 42 . Taken together, we have identified PIM1 substrates which are involved in regulating cell cycle, nucleic acid metabolism, cell signaling, and cell migration.
To validate the substrates identified in our screen, we tested endogenous thiophosphorylation of PUM1, NDRG1, CHMP7, and KIF18A in LNCaP-AS PIM1 versus
LNCaP-WT PIM1 cells. All four proteins were thiophosphorylated in the presence of PhET-ATPγS by AS PIM1 to a greater extent than by WT PIM1 (Fig. 3A-D) . To confirm the sites of phosphorylation, we generated serine/threonine to alanine mutants of each substrate and coexpressed them with AS PIM1 in 293T cells. We performed the thiophosphorylation assay, including alkylation with pNBM, immunoprecipitated the substrate of interest, and performed Western blot using a thiophosphate ester specific antibody. We observed reduced thiophosphorylation in the phospho-mutant substrates ( Fig. 3E -H), indicating that these are the predominant sites of PIM1-mediated phosphorylation for each substrate. This data provides strong evidence that the proteins identified in our screen are bona fide PIM1 substrates in prostate cancer cells.
NDRG1 phosphorylation varies in prostate cancer cells and tissues
We focused on characterizing the effect of PIM1-dependent serine 330 phosphorylation (pS330) of NDRG1, given that a phosphoproteomic analyses of prostate cancer tissues by Drake et al. demonstrated that levels of NDRG1 pS330 were found to be 7.7 times higher in metastatic lesions than in localized prostate cancer 43 (Sup Table 5 ). Although several studies have implicated NDRG1 in prostate cancer 44, 45 , a link between PIM1 and NDRG1 has not been established. NDRG1 is a member of the alpha/beta hydrolase superfamily, but does not possess catalytic activity 46 . It has been well documented as a potent inhibitor of tumor growth and cancer cell proliferation and an inhibitor of cell migration and invasion 47 . Its expression alters the levels and membrane localization of beta-catenin and the membrane glycoprotein KAI1 (CD82), leading to increased cell-cell adhesion 48 . Additionally, overexpression of NDRG1 reduces metastasis in a rodent model of prostate cancer 49 . In contrast, prostate cancer cells with low NDRG1 expression display increased motility and invasiveness 45 , and reduced expression of NDRG1 was associated with poor overall survival in a variety of cancers, including prostate 50 . NDRG1 is transcriptionally regulated by the androgen receptor 51 .
Considering this information, we examined the protein levels of NDRG1 pS330, total NDRG1, and PIM1 by immunohistochemistry using tissue microarrays containing primary prostate tumors and adjacent non-cancer tissue (Suppl. protein abundance (p=0.583), suggesting that the change in NDRG1 pS330 was a result of increased phosphorylation by PIM1 ( Fig. 4C ).
We next probed a panel of prostate cancer cell lines for NDRG1 pS330, total NDRG1, and PIM1 by Western blot. AR expressing prostate cancer lines displayed varying levels of NDRG1 pS330. VCaP cells, a prostate cancer cell line with AR amplification, displayed the highest level of total NDRG1 and NDRG1 pS330, consistent with our findings that NDRG1 expression and phosphorylation are androgen regulated ( Fig. 4D ; Suppl. Fig. 1 ). Together, these results demonstrate that NDRG1 pS330 is correlated with high grade prostate cancers (high Gleason score), and that NDRG1 pS330 is present in multiple prostate cancer cell lines.
NDRG1 protein is destabilized by PIM1-mediated phosphorylation
We next investigated the effect of androgens on NDRG1 pS330. As expected, in the absence of androgens, LNCaP cells overexpressing WT PIM 14 have increased levels of NDRG1 pS330 ( Fig. 5A ). Treatment with the androgen dihydrotestosterone (DHT) increased NDRG1 pS330 compared to untreated cells. LNCaP cells treated with DHT and with SGI-1776, a potent and specific PIM1 inhibitor 52 , resulted in decreased NDRG1 pS330 ( Fig. 5B ). PIM1 knockdown by siRNA treatment also reduced NDRG1 pS330 ( Fig. 5C ). This indicates that NDRG1 phosphorylation at S330 is mediated by PIM1, and inhibition or knockdown of PIM kinase activity decreases phosphorylation.
To determine whether phosphorylation affects the stability of NDRG1, we examined NDRG1 stability by blocking protein synthesis with cycloheximide and tracking NDRG1 abundance over time. We co-expressed WT or phospho-mutant (S330A) NDRG1 with either empty vector or WT PIM1 in 293 cells. Compared with empty vector alone, co-expression of WT NDRG1 with WT PIM1 led to a significant reduction in NDRG1 protein stability ( Fig. 5D ).
NDRG1 is exceedingly stable in the absence of PIM1, with its abundance unchanged over 24 hours in the presence of cycloheximide. However, the addition of PIM1 resulted in a decrease in NDRG1 abundance by 50% at 24 hours ( Fig 5D) . Treatment with the proteasome inhibitor MG-132 in the presence of PIM1 restored NDRG1 stability, indicating that degradation is occurring via the proteasome. By contrast, NDRG1 S330A mutant was resistant to degradation in the presence of PIM1 ( Fig 5D) . Finally, we examined the endogenous levels of NDRG1 in LNCaP cells in the presence of PIM1 and found that PIM1 overexpression results in a reduction of NDRG1 protein ( Fig 5E) . Collectively, we find that PIM1 expression leads to increased levels of NDRG1 pS330, and PIM1-dependent NDRG1 phosphorylation decreases NDRG1 protein stability.
Non-phosphorylated NDRG1 localizes to the nucleus and interacts with the androgen receptor
We next examined the subcellular distribution of NDRG1 pS330 and total NDRG1 in prostate cancer cells. PIM1 has been reported to be mainly localized to the cytoplasm 53 . LNCaP and VCaP cells were separated into cytoplasmic, membrane, soluble nuclear, and chromatin bound fractions, and probed for NDRG1 pS330 and total NDRG1 by Western blot. In both cell lines, NDRG1 pS330 was largely detected in the cytoplasmic fraction, with a small amount of NDRG1 pS330 in the membrane fraction of VCaP cells. The faster migrating NDRG1 species in the soluble nuclear fraction from LNCaP cells may represent a previously described C-terminally truncated variant of NDRG1 54 . By contrast, total NDRG1 was detected across all fractions, including the nuclear fractions ( Fig. 6A ). We hypothesized that phosphorylation may prevent NDRG1 from accumulating in the nucleus.
Prostate cancer is highly dependent on AR transcriptional activity 55 . For this reason, we examined whether NDRG1 interacts with AR and affect its transcriptional activity. We immunoprecipitated endogenous NDRG1 from LNCaP cells, with or without PIM1 overexpression ( Fig. 6B ). We were able to observe co-immunoprecipitation of AR with NDRG1.
Additionally, consistent with our previous results, the overexpression of PIM1 reduced the abundance of NDRG1 protein, resulting in a reduction in immunoprecipitated NDRG1 and AR.
Next, to determine whether S330 phosphorylation affects the interaction between NDRG1 and AR, we over-expressed WT or S330A NDRG1 in 293T cells ( Fig. 6C ). We immunoprecipitated AR and observed that it interacts more robustly with NDRG1 S330A than WT NDRG1. This suggests that non-phosphorylated form of NDRG1 is more capable of interacting with AR potentially through alterations in its abundance or localization.
Because we observed an interaction between AR and NDRG1, we tested whether NDRG1 affected AR transcriptional activity. We transfected LNCaP cells with NDRG1 or the non-phosphorylatable NDRG1 S330A, in the absence and presence of PIM1, and assayed the expression of AR target genes PSA and NKX3.1. Expression of WT NDRG1, and to a greater extent S330A, decreased androgen-dependent expression of PSA and NKX3.1 (Fig. 6D , Suppl. Fig. 2A ). Co-expression of PIM1 with NDRG1 rescued the PSA and NKX3.1 expression in the presence of WT NDRG1, but not NDRG1 S330A. This suggests that NDRG1 negatively regulates AR activity, and that PIM1-dependent NDRG1 pS330 reverses this effect. Collectively, this data suggests that non-phosphorylated NDRG1 interacts with and represses AR transcriptional activity, and upon phosphorylation at S330 by PIM1, this interaction and corepression is reduced.
NDRG1 pS330 is associated with inhibition of prostate cancer cell migration and invasion
Multiple reports have illustrated the role of NDRG1 as a metastasis suppressor 42, 45, 56 .
For example, overexpression of NDRG1 in a mouse xenograft model reduced lung and liver metastasis 57 . NDRG1 regulates the expression of the membrane protein KAI1 (CD82), which interacts with adjacent cells via the membrane protein gp-Fγ to inhibit metastasis 57 . Moreover, NDRG1 expression in HepG2 cells leads to increased membrane-localized beta-catenin, which promotes a less migratory phenotype and greater cell-cell contact 45 . In light of these findings, and given the previously demonstrated ability of PIM1 to promote cell migration and invasion 58, 59 , we investigated the effect of NDRG1 phosphorylation on the migration and invasion of prostate cancer cells. To examine migration, we exogenously expressed WT NDRG1 or NDRG1 S330A in PIM1 overexpressing LNCaP and VCaP cells (Suppl. Fig. 2C ), and used a scratch assay to monitor migration over 72 hours. In LNCaP-WT PIM1 expressing cells, there was an 80% scratch area recovery after 72 hours. WT NDRG1 overexpression was unable to suppress this cell migration, but in cells expressing NDRG1 S330A, there was only a 50% recovery ( Fig. 6E ). Likewise, in VCaP cells expressing WT PIM1 alone or with WT NDRG1, 100% scratch closure was observed after 72 hours, and the area recovery was only 33% in cells expressing NDRG1 S330A (Fig. 6E ). Knockdown of NDRG1 by siRNA in LNCaP cells also increased cell migration (Suppl. Fig. 2B ). Similar results were observed in a matrigel invasion assay. In LNCaP and VCaP cells co-expressing WT PIM1 and WT NDRG1, there was no difference in invasion. However, in cells expressing NDRG1 S330A, there was a significant reduction in cell invasion ( Fig. 6F ). KAI1 expression is also increased in with overexpression of NDRG1 S330A in LNCaP cells (Suppl. Fig. 2D ). These results suggest that phosphorylation of NDRG1 reduces its function as a suppressor of migration and invasion, and that blocking PIM1dependent NDRG1 phosphorylation could restore its metastasis suppressor function
DISCUSSION
Our screen is the first to use an unbiased, direct method to identify PIM1 substrates in prostate cancer cells. We identified 25 previously unknown PIM1 substrates and their phosphorylation sites. We demonstrated that the specificity of the AS PIM1 was retained, as AS PIM1 is still able to thiophosphorylate the known PIM1 substrate, AR 14 . Of the 25 substrates that were present in AS PIM1 and not WT PIM1, 15 were identified in two biological replicates, and the phosphorylation sites conform to the PIM1 consensus sequence. We validated four of these targets using alkylation and detection by western blot. Our screen, however, was not comprehensive, and did not identify other previously identified PIM1 substrates, such as c-MYC.
This may reflect low abundance of the phosphorylated substrates in LNCaP cells, or may be due to the fact that not all tryptic peptides are equally eluted from iodoacetyl beads or equally detectable by mass spectrometry. Additionally, our approach represents a direct, unbiased approach to identifying PIM1 substrates in prostate cancer cells. Therefore, these substrates may be the most representative of PIM1 activity in prostate cancer. In fact, PIM1 has overlapping substrate specificity with AKT protein kinases: for example, both have been shown to phosphorylate the pro-apoptotic protein BAD 60, 61 . However, data from in vivo studies using knock-out mice indicate that AKT and PIM kinases are mechanistically distinct in the control of hematopoietic cell proliferation 62 . This reinforces the notion that identification of direct PIM1
targets is key to elucidating its function in a given cell type.
We have found that PIM1 substrates are involved in multiple physiological processes.
Network enrichment analysis of all 25 substrates using Metascape 63 [http://metascape.org] revealed functional classes including chromosome segregation, pre-RNA complex, nucleotide catabolic processes, transcriptional regulation, and infectious disease (Suppl. Fig. 3A ). This is consistent with studies of PIM1's effect on cell cycle, transcription, and cell motility. In addition, a majority of the substrates fall into a protein interaction network that suggests PIM1 phosphorylation may coordinate protein complexes to impact cellular function (Suppl. Fig. 3B ).
Further studies will be required to validate the interaction network and determine whether these associations are phosphorylation dependent.
Among the newly identified PIM1 substrates, we focused on NDRG1. NDRG1 was shown to be as an inhibitor of metastasis. Its expression alters the expression and membrane localization of beta-catenin and the membrane glycoprotein KAI1 (CD82), leading to increased cell-cell adhesion 57 . NDRG1 is transcriptionally regulated by AR, which is also phosphorylated by PIM1. In addition, Drake et al. reported that the level of NDRG1 pS330 was higher in metastatic castration resistant prostate cancer (CRPC) lesions than in treatment naïve, localized prostate cancer 43 . This was the only phosphorylation site identified in our screen that was increased in metastatic compared to localized prostate cancer (Suppl. Table 5 ).
Immunohistochemical analysis of prostate cancer tissue microarrays showed a significant increase in NDRG1 pS330 in malignant compared to benign tissues. This correlates with the low expression of PIM1 in benign tissues and moderate to high PIM1 expression in prostate cancer 12 . PIM1-dependent phosphorylation of NDRG1 appears to also reduce its stability, with the NDRG1 S330A mutant showing an increased half-life in the presence of PIM1. Previous studies have suggested that NDRG1 protein stability is reduced by the fusion of SUMO2 to NDRG1 64 . Whether phosphorylation of NDRG1 results in NDRG1 sumolyation to control protein stability remains to be addressed.
The migratory and invasive potential of cancer cells are key mediators of metastasis 18 .
PIM1 expression has been correlated with lymph node metastasis and poor prognosis in patients with lung adenocarcinoma and squamous cell carcinoma 65 . We were interested in how PIM1 kinase activity could promote metastasis via one of the substrates we identified. Indeed, the non-phosphorylatable NDRG1 S330A suppressed migration and invasion of LNCaP and VCaP cells. We have shown that PIM1 phosphorylation of NDRG1 reduces its stability, reduces its nuclear localization, reduces its interaction with AR, and therefore relieves AR co-repression.
This suggests that PIM1-mediated phosphorylation of NDRG1 inhibits its ability to exert metastasis-suppressive functions in prostate cancer. Our results establish an understanding of how phosphorylation inhibits the function of NDRG1 in suppressing migration and invasion.
Based on these findings, we propose a model whereby PIM1 is, in part, imposing its oncogenic function by phosphorylating NDRG1 to reduce its metastasis suppressor activity (Fig. 6G ).
Thus, identifying direct substrates has allowed for the characterization of the mechanism by which PIM1 mediates an oncogenic phenotype -namely cell migration and invasion -in the context of prostate cancer. We anticipate that characterization of additional PIM1 substrates will lend further mechanistic insights into the oncogenic properties imparted by PIM1 in prostate cancer.
Methods
Cell Culture and Reagents
Cell lines used in this study were purchased from ATCC, with the exception of LNCaP-95 66 , LNCaP-abl 67 
Quantitative RT-PCR
Total RNA was extracted and quantitative RT-PCR was performed as previously described 14 . Primers can be found in Supplemental Table 6 .
Transfection and Transduction
Transient transfections were carried out utilizing Lipofectamine 2000 (Invitrogen)
according to the manufacturer's protocol. Viral transductions were carried out in 293T cells (4.5 
Thiophosphorylation of PIM1 Substrates
Thiophosphorylation experiments were carried out as described with minor selected as variable modifications. Both precursor and fragment mass tolerances were set to 10 ppm. All identified peptides were filtered using a Byonic score of >200. And a falsediscovery rate (FDR) of 0.01 was applied for protein level identification.
Immunoprecipitation of Candidate Substrates
For immunoprecipitation after thiophosphorylation and alkylation referred to in "Thiophosphorylation of PIM1 Substrates" (Fig.3) , 40 μ l out of 500 μ l lysate was retained to evaluate expression. The remaining lysate was incubated with 25 μL of FLAG agarose beads (M2, Sigma, F2426) pre-washed 3 X in bead wash buffer (50 mM Tris HCl pH 7.5, 100 mM NaCl, 5 mM EDTA, and 0.4% Triton-X), and incubated for 2 h at 4 o C with end-over-end rotation.
In order to recover immunoprecipitated protein, beads were washed 5X with bead wash buffer containing protease inhibitors. To elute proteins, beads were incubated with 100μL TBS containing FLAG peptide for 1 h at 4 o C with end-over-end rotation. Beads were pelleted and the 6X SDS loading buffer added to eluted proteins in the supernatant and boiled for 5 min. Proteins were resolved by SDS-PAGE and analyzed by western blotting with the appropriate antibodies. 
Migration and Matrigel Invasion Assay
For the migration assay, LNCaP and VCaP cells were plated in 6-well plates, at 500,000 cells per well and transfected with indicated constructs using Lipofectamine 2000 according to manufacturer's instructions. After 48 h, cells were plated into 2 well silicone insert with a defined cell-free gap, according to manufacturer's instructions (#81176, Ibidi USA). LNCaP cells were plated at 350,000/mL, and VCaP cells were plated at 850,000/mL. After an overnight incubation, the inserts were removed, and images captured after 72 h. Images were obtained at 5X magnification utilizing an EVOS FLc. The area remaining was measured by ImageJ software in arbitrary units, with error bars representing standard deviation for three independent experiments performed in triplicates (**P value=0.05, Student's t-test). For the invasion assay, matrigel-coated chambers were rehydrated with serum-free DMEM. 100,000 LNCaP or VCaP cells were added to the upper chamber in 500µL of media. In the lower chamber 500µL of complete media was added to serve as the chemoattractant. After 48 h, cells that did not invade matrigel were cleared away using a cotton swab, and remaining cells were stained with 0.05% crystal violet dye. For quantification, chambers were incubated for 2 mins in 150µL of 10% acetic acid in dH 2 O to solubilize the dye taken up by the cells and quantified spectrophotometrically at 570 nm.
Human Prostate Cancer Tissue Microarrays, Immunohistochemistry, and Scoring
Human prostate tissue microarrays are from US Biomax, Inc. (Rockville, MD) (cat # PR803a and PR807b). Tissues slides were deparaffinized and rehydrated in xylenes and a series of graded ethanol. Antigen retrieval was performed with 0.01 M citrate buffer at pH 6.0 for 20 minutes at 95°C. Slides were allowed to cool for another 30 minutes, followed by sequential rinsing in phosphate-buffered saline with 0.01% Triton X (PBS-T). Endogenous peroxidase activity was quenched by incubation in PBS-T containing 3% hydrogen peroxide. Each incubation step was carried out at room temperature and was followed by three sequential washes in PBS-T. Sections were incubated in 5% normal goat serum in RT for 1 h before incubation with rabbit polyclonal NDRG1 pS330, total-NDRG1, PIM1, AR pS213 and total AR (441) antibodies, overnight at 4°C. The next day, slides were washed with PBS-T three times and were incubated with biotinylated secondary antibody for 1 h, peroxidase-labeled streptavidin was quantitated. Invasion assay through matrigel was performed in LNCaP-PIM1 and VCaP-PIM1 cells expressing the indicated NDRG1 constructs, and cells invading through matrigel were stained and shown as micrographs. The stain was extracted from the cells that migrated through the matrigel and quantitated spectrophotometrically at 595 nm wavelength. G) Model illustrating the effect of PIM1 phosphorylation on NDRG1 and its co-repression of AR.
Supplemental Figure 1 . NDRG1 expression is stimulated by androgen-treatment in LNCaP cells. LNCaP cells were steroid-starved for 48 h, and treated with 10 nM DHT for 24 h. mRNA levels for PSA, and PIM1 substrates relative to RPL19 were analyzed by qRT-PCR. Figure 6 . A) LNCaP cells were transfected with the empty vector, NDRG1 or NDRG1 S330A, without or with PIM1, steroidstarved for 48 h, and treated with 10 nM DHT for 24 h. mRNA expression of Nkx3.1 was measured by qRT-PCR relative to RPL19. B) LNCaP cells were transfected with either nontargeting siRNA (siControl) or NDRG1 siRNA (siNDRG1). After 48 h, cells were plated for migration assay, and area remaining quantified by ImageJ analysis. Inset illustrates NDRG1 knockdown by siRNA by Western blot. C) Western blot analysis from LNCaP and VCaP cells of exogenously expressing empty vector (-), wild type NDRG1 (WT), or NDRG1 S330A (SA) in the presence of WT PIM1. HSP90 was used as loading control. D) (Pertaining to Figure 6D -E) LNCaP cells were transfected with either NDRG1 WT or NDRG1 S330A and/or WT PIM1 or kinase dead (KD) PIM1, and KAI1 gene expression was measured by qRT-PCR relative to RPL19. Supplemental Table 1 . PIM1 gatekeeper residue alignment with kinases that analog-sensitive mutants have been generated for 22, 28, [69] [70] [71] [72] .
Supplemental Figure 2. Supplemental Figures associated with
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Supplemental Table 2 . PIM1 substrates identified from LNCaP cells. UniProt accession ID, phosphorylation site, peptide count from two independent experiments, validation status, and function are listed.
Supplemental Table 3 . PIM1 substrate phosphorylation site alignment.
Supplemental Table 4 . Prostate tumor microarray sample data, scoring and statistical analysis.
Supplemental Table 5 . PIM1 substrate phosphorylation in metastatic versus primary prostate cancer from Drake el al. 43 Supplemental Table 6 . Primers for qRT-PCR of PIM1 substrates.
